BDX

MKT CAP:$55B

Becton, Dickinson and Company

Market Cap

$55B

Healthcare·Medical - Instruments & Supplies·🇺🇸 United States·NYSE

Healthcare·Medical·🇺🇸·NYSE

Stock Price

$152.53-$0.72 (-0.47%)

Apr 24, 2026

Company Details

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutica...

CEO

Thomas E. Polen Jr.

IPO Date

Feb 21, 1973

Website

www.bd.com

Key Metrics TTM

Revenue

$21.3B

+9.5% YoY

Net Income

$1.7B

EPS (Diluted)

$5.78

Free Cash Flow

$3.2B

Revenue / Share

$74.72

Gross Margin

45.5%

Operating Margin

11.0%

Net Margin

7.8%

FCF Margin

15.1%

P/S

2.6x

P/E

33.1x

Earnings Reports

Q2 2026

May 7, 2026

PENDING

Q1 2026

Feb 9, 2026

$5.3B+1.6%EPS $1.34

FY 2025

Nov 25, 2025

$21.8B+8.2%EPS $5.83

Q4 2025

Nov 25, 2025

$5.9BEPS $1.72

Q1 2025

Feb 6, 2025

$5.2B+9.8%EPS $1.04

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 20	$4.8B	$2.2B	$255M
Q1 21	$5.3B	$2.7B	$1.2B
Q2 21	$4.9B	$2.2B	$434M
Q3 21	$4.6B	$2.0B	$492M
Q4 21	$5.1B	$2.3B	$495M
Q1 22	$4.7B	$2.2B	$692M
Q2 22	$4.8B	$2.1B	$564M
Q1 23	$4.6B	$2.1B	$585M
Q2 23	$4.8B	$2.2B	$628M
Q3 23	$4.9B	$2.1B	$549M
Q1 24	$4.7B	$2.0B	$439M
Q2 24	$5.0B	$2.3B	$734M
Q3 24	$5.0B	$2.3B	$602M
Q1 25	$5.2B	$2.2B	$453M
Q4 25	$5.9B	$2.8B	$697M
Q1 26	$5.3B	$2.3B	$594M

Valuation

Quarter	P/S	P/E
Q4 20	2.3x	45.0x
Q1 21	2.4x	27.2x
Q2 21	2.3x	25.3x
Q3 21	2.2x	21.7x
Q4 21	2.2x	20.7x
Q1 22	2.2x	24.6x
Q2 22	2.4x	24.0x
Q1 23	2.3x	23.3x
Q2 23	2.3x	20.8x
Q3 23	2.5x	25.7x
Q1 24	2.3x	26.8x
Q2 24	2.2x	25.9x
Q3 24	2.1x	24.0x
Q1 25	2.0x	25.2x
Q4 25	1.5x	17.9x
Q1 26	2.1x	26.3x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 20	$1.5B	$1.3B
Q1 21	$1.5B	$1.3B
Q2 21	$1.2B	$935M
Q3 21	$975M	$708M
Q4 21	$951M	$486M
Q1 22	$674M	$486M
Q2 22	$444M	$217M
Q1 23	$400M	$192M
Q2 23	$184M	$3M
Q3 23	$1.1B	$889M
Q1 24	$841M	$725M
Q2 24	$515M	$381M
Q3 24	$1.3B	$1.1B
Q1 25	$693M	$588M
Q4 25	$1.4B	$1.0B
Q1 26	$657M	$549M

Capital Expenditures

Quarter	CapEx
Q4 20	$213M
Q1 21	$246M
Q2 21	$253M
Q3 21	$267M
Q4 21	$465M
Q1 22	$188M
Q2 22	$227M
Q1 23	$208M
Q2 23	$181M
Q3 23	$191M
Q1 24	$116M
Q2 24	$134M
Q3 24	$179M
Q1 25	$105M
Q4 25	$352M
Q1 26	$108M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 20	+4.4%	+1.3%
Q1 21	+25.8%	+9.4%
Q2 21	+15.4%	+15.2%
Q3 21	+19.5%	+17.7%
Q4 21	+7.3%	+2.5%
Q1 22	-11.2%	-1.2%
Q2 22	-3.2%	-6.4%
Q1 23	-0.5%	-2.8%
Q2 23	-6.1%	-9.6%
Q3 23	+3.4%	+7.5%
Q1 24	-0.9%	+1.9%
Q2 24	+10.0%	+7.7%
Q3 24	+3.5%	+4.7%
Q1 25	+5.9%	+8.9%
Q4 25	+25.2%	+21.7%
Q1 26	+4.1%	+8.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 20	$51M	1.1%
Q1 21	$83M	1.6%
Q2 21	$55M	1.1%
Q3 21	$51M	1.1%
Q4 21	$48M	0.9%
Q1 22	$83M	1.8%
Q2 22	$57M	1.2%
Q1 23	$89M	1.9%
Q2 23	$56M	1.2%
Q3 23	$56M	1.1%
Q1 24	$83M	1.8%
Q2 24	$60M	1.2%
Q3 24	$53M	1.1%
Q1 25	$90M	1.7%
Q4 25	$55M	0.9%
Q1 26	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 20	$299M	—	$1.2B
Q1 21	$291M	—	$1.1B
Q2 21	$317M	—	$1.1B
Q3 21	$330M	—	$1.2B
Q4 21	$387M	—	$1.3B
Q1 22	$314M	—	$1.2B
Q2 22	$327M	—	$1.2B
Q1 23	$313M	—	$1.2B
Q2 23	$337M	—	$1.2B
Q3 23	$306M	—	$1.2B
Q1 24	$290M	—	$1.2B
Q2 24	$299M	—	$1.2B
Q3 24	$299M	—	$1.2B
Q1 25	$343M	—	$1.3B
Q4 25	$322M	—	$1.4B
Q1 26	$318M	$1.4B	—

Revenue Segments

Quarter	Interventional	Life Sciences	Medical
Q4 20	$978M	$1.5B	$2.3B
Q1 21	$1.1B	$2.0B	$2.3B
Q2 21	$1.0B	$1.6B	$2.3B
Q4 21	$1.1B	$1.5B	$2.5B
Q1 23	$1.1B	$1.3B	$2.2B
Q2 23	$1.2B	$1.3B	$2.4B
Q3 23	$1.2B	$1.2B	$2.4B
Q1 24	$1.2B	$1.3B	$2.2B
Q2 24	$1.3B	$1.3B	$2.4B
Q3 24	$1.2B	$1.3B	$2.6B
Q1 25	$1.3B	$1.3B	$2.6B
Q4 25	$1.4B	$1.4B	$3.2B

Revenue by Geography

Quarter	Non-US	United States
Q4 20	$2.0B	$2.8B
Q1 21	$2.2B	$3.1B
Q2 21	$2.4B	$2.5B
Q4 21	$2.3B	$2.8B
Q1 23	$1.9B	$2.7B
Q2 23	$2.1B	$2.7B
Q3 23	$2.1B	$2.8B
Q1 24	$2.0B	$2.7B
Q2 24	$2.1B	$2.9B
Q3 24	$2.1B	$2.9B
Q1 25	$2.1B	$3.1B
Q1 26	$2.1B	$3.2B

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 22	$3.1B	$15M	$3.2B
Q3 22	$2.6B	$14M	$2.6B
Q4 22	$1.0B	$8M	$1.0B
Q1 23	$612M	$0	$612M
Q2 23	$2.0B	$6M	$2.0B
Q3 23	$923M	$8M	$931M
Q4 23	$1.4B	$8M	$1.4B
Q1 24	$1.2B	$2M	$1.2B
Q2 24	$2.3B	$827M	$3.2B
Q3 24	$4.5B	$851M	$5.3B
Q4 24	$1.9B	$445M	$2.3B
Q1 25	$711M	$17M	$728M
Q2 25	$667M	$16M	$683M
Q3 25	$735M	$22M	$757M
Q4 25	$851M	$8M	$859M
Q1 26	$1.0B	$11M	$1.0B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 20	293M	+2.9%	+6.7%
Q1 21	293M	-0.1%	+6.6%
Q2 21	294M	+0.1%	+6.7%
Q3 21	292M	-0.6%	+2.4%
Q4 21	289M	-1.1%	-1.6%
Q1 22	287M	-0.6%	-2.2%
Q2 22	287M	+0.2%	-2.1%
Q1 23	285M	-0.7%	-2.2%
Q2 23	286M	+0.1%	-1.0%
Q3 23	288M	+0.8%	+0.4%
Q1 24	291M	+1.2%	+1.4%
Q2 24	290M	-0.4%	+1.8%
Q3 24	290M	-0.0%	+1.6%
Q1 25	290M	+0.0%	+0.8%
Q4 25	287M	-1.1%	-1.5%
Q1 26	285M	-0.7%	-1.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 20	$66.4K	72K
Q1 21	$73.8K	72K
Q2 21	$68.2K	72K
Q3 21	$64.0K	72K
Q4 21	$68.5K	75K
Q1 22	$62.9K	75K
Q2 22	$63.3K	75K
Q1 23	$59.6K	77K
Q2 23	$62.6K	77K
Q3 23	$63.4K	77K
Q1 24	$64.5K	73K
Q2 24	$69.1K	73K
Q3 24	$68.4K	73K
Q1 25	$69.8K	74K
Q4 25	$81.8K	72K
Q1 26	$72.9K	72K

Revenue / Employee